glp-1 agnoist Agonists in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies Current Insights, Advantages and Challenges

There was no head-to-head trial directly comparing these antidiabetic drug classes

These associations remained consistent across subgroup analyses, including patients using tirzepatide as adjunctive therapy to other first-line diabetes agents, among patients older than 60 and comparisons against individual GLP-1 drugs, including semaglutide and dulaglutide

The Extended Lifespan of GLP-1 Receptor Agonist Drugs from the Discovery of Pleiotropic Effects Glucagon-like peptide-1 (GLP-1) was first discovered in the 1980s as a regulator of glucose levels

Whether you are located in Bend, Oregon, Seattle, Washington, or receiving care in California, Oregon, or Washington through telehealth, our team is available to help answer questions about your medication and treatment plan